Cord Blood (CB) is a potential source of primitive hematopoietic progenitors that may be used for ex-vivo expansion. We demonstrated that CB CD34+ cells can be grown in stroma-free suspension cultures in the presence of SCF+FL+TPO+IL6 for up to 10 weeks, undergo a large expansion of committed unipotent and multipotent progenitors without losing their in vivo repopulation capacity. In this study we assessed whether expanded cells retained their capacity to self-renew. To answer this question human CD45+ or CD34+ cells were separated from the bone marrow of engrafted primary recipients and transplanted into secondary mice. Bone marrow cells of the secondary mice were composed by human CD45+, and all of the different lineages were represented. Human engraftment was determined by FACS analysis and by semisolid culture assays. Human cells represented 4.8 to 21.2% of the total BM cells. Human CD45+ and CD34+ cells were again separated from the BM and injected into sublethally irradiated tertiary recipients and the presence of human cells in the transplanted animals assessed after 6-8 weeks. Human cells were present in all of the evaluated cases, their percentage ranging from 3.4 to 12%. Again, cells belonging to all of the hemopoietic lineages were represented. The transplanted cells, derived from initial CB CD34+ cells consisted of both CD34+ and CD34-Lin+ cells, therefore it was not possible to ascertain whether the observed engraftment was due to expanded CD34+ cells or, rather, to expanded accessory cells. To address this issue expanded CD34+ cells were transplanted as they were a or after separation into CD34+ and CD34-cells. CD34+ were injected alone or co-transplanted with irradiated or non irradiated CD34-cells. Similar levels of engraftment were detected when NOD/SCID mice were transplanted with CD34+ cells alone or together with irradiated or non irradiated CD34-cells. When CD34-cells were injected human engraftment could not be detected. In order to assess the frequency of SCID Repopulating Cells (SRC) in the expanded and re-isolated CD34+ cells, limiting dilution repopulation studies were performed by injecting decreasing concentrations of CD34+ cells in cohorts of sublethally irradiated mice. Good levels of engraftment were detected upon injection of 1x10e5 down to 2x10e4 expanded, isolated CD34+ cells after 4 to 8 weeks of expansion, suggesting that a real expansion of in vivo repopulating cells was occurring.
M. Aglietta, M. Gunetti, S. Bruno, L. Gammaitoni, F. Fagioli, W. Piacibello (Torino, I) Cord Blood (CB) is a potential source of primitive hematopoietic progenitors that may be used for ex-vivo expansion. We demonstrated that CB CD34+ cells can be grown in stroma-free suspension cultures in the presence of SCF+FL+TPO+IL6 for up to 10 weeks, undergo a large expansion of committed unipotent and multipotent progenitors without losing their in vivo repopulation capacity. In this study we assessed whether expanded cells retained their capacity to self-renew. To answer this question human CD45+ or CD34+ cells were separated from the bone marrow of engrafted primary recipients and transplanted into secondary mice. Bone marrow cells of the secondary mice were composed by human CD45+, and all of the different lineages were represented. Human engraftment was determined by FACS analysis and by semisolid culture assays. Human cells represented 4.8 to 21.2% of the total BM cells. Human CD45+ and CD34+ cells were again separated from the BM and injected into sublethally irradiated tertiary recipients and the presence of human cells in the transplanted animals assessed after 6-8 weeks. Human cells were present in all of the evaluated cases, their percentage ranging from 3.4 to 12%. Again, cells belonging to all of the hemopoietic lineages were represented. The transplanted cells, derived from initial CB CD34+ cells consisted of both CD34+ and CD34-Lin+ cells, therefore it was not possible to ascertain whether the observed engraftment was due to expanded CD34+ cells or, rather, to expanded accessory cells. To address this issue expanded CD34+ cells were transplanted as they were a or after separation into CD34+ and CD34-cells. CD34+ were injected alone or co-transplanted with irradiated or non irradiated CD34-cells. Similar levels of engraftment were detected when NOD/SCID mice were transplanted with CD34+ cells alone or together with irradiated or non irradiated CD34-cells. When CD34-cells were injected human engraftment could not be detected. In order to assess the frequency of SCID Repopulating Cells (SRC) in the expanded and re-isolated CD34+ cells, limiting dilution repopulation studies were performed by injecting decreasing concentrations of CD34+ cells in cohorts of sublethally irradiated mice. Good levels of engraftment were detected upon injection of 1x10e5 down to 2x10e4 expanded, isolated CD34+ cells after 4 to 8 weeks of expansion, suggesting that a real expansion of in vivo repopulating cells was occurring.
P788 CGMP produced mesenchymal stem cells (allogen) support in vitro hematopoiesis
M. Sumner, C. Guevarra, D. Simonetti, M. Jennings, R. Deans, A. MacKay (Baltimore, USA)
Certain human bone marrow stromal cells can be isolated and expanded in adherent culture and retain the ability to differentiate to multiple connective tissue lineages, warranting the name human mesenchymal stem cells (hMSCs). Preclinical studies suggest that culture-expanded MSCs can integrate into connective tissue compartments of numerous organs when introduced by direct implantation, intravenous injection or intra-uterine transplantation. Cultured hMSCs produce numerous membrane-bound and secreted proteins known to influence hematopoiesis, and are able to support hematopoietic stem cell (HSC) proliferation and differentiation. Allogen is a clinically manufactured MSC product currently in Phase II trials for facilitating the engraftment of transplanted allogeneic hematopoietic cells. The purpose of this study was to define conditions for Allogen support of CD34+ proliferation and differentiation in vitro. CD34+ cells were cultured with Allogen clinical samples, using the Transwell system to preclude direct contact. Allogen cell product from twelve clinical donors were seeded in triplicate 35 mm wells. Into each well was placed a Transwell with 260,000 CD34+-selected mobilized peripheral blood cells. Cultures were held at 33 C for 7 weeks, and fed twice weekly with MyeloCult medium. Hematopoietic cells were then analyzed by flow cytometry, and put into methylcellulose colony assays. All 12 MSC donors had similar effects on the co-cultured hematopoietic cells. The HSCs underwent (8±2)-fold proliferation, and a small number of cells retained the CD34+ primitive-cell phenotype (2.4±0.8%). Few cells (Ͻ2%) were positive for markers CD3, CD41, CD19, or GlyA, but differentiation to the monocytic lineage (CD14; 9±2%) was consistently observed. Flow analysis thus implied that most cells progressed to partially-committed precursor cells. At the end of the 7 weeks of co-culture, the hematopoietic cell populations were able to found 7600±1700 CFU-GM, 400±170 BFU-E, and 67±36 CFU-GEMM colonies. In comparison, the initial population of CD34+ cells yielded 6000 CFU-GM, 5800 BFU-E, and 210 CFU-GEMM colonies. Thus, CFU-GM activity underwent a slight increase during prolonged co-culture, while diminished but significant BFU-E and CFU-GEMM activity persisted. This in vitro support of hematopoiesis is consistent with the improved hematopoietic engraftment seen in ongoing clinical studies of the Allogen cell product.
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Multilineage potential of human mesenchymal stem cells: bone marrow versus cord blood K. Mareschi, E. Biasin, M. Berger, L. Fazio, W. Piacibello, M. Aglietta, E. Madon, F. Fagioli (Torino, I) OBJECTIVE: in addition to hemopoietic stem cells, bone marrow also contains mesenchymal stem cells which contribute to the regeneration of mesenchymal tissues, such as bone, cartilage, adipose, muscle, ligament, tendon and stroma. In this study we tried to isolate and characterise mesenchymal stem cells from bone marrow and from cord blood. MATERIALS and METHODS: thirty bone marrow and 47 cord blood samples were harvested. Light density cells were isolated by density gradient (Percoll 1.073g/L) and cultured in a-Mem+10%Fetal Bovine Serum +10%Horse Serum. When the cultures generated a confluent layer, cells were recovered by the addition of a solution containing 0,25% trypsin-EDTA and/or by scraper. Secondary cultures under conditions that were favourable for adipogenic, chondrogenic and osteogenic differentiation were prepared. Adipogenic differentiation was induced by treatment with 1-methyl-3-isobutylxanthine, dexamethasone, insulin and indomethacin and after 2 weeks was indicated by accumulation of lipid-rich vacuoles within cells positive for Oil Red O staining and by Lipoprotein Lipase mRNA. To promuove chondrogenic differentiation cells were cultivated as a pelleted micromass in medium without serum and with Transforming Growth Beta-3. Alcian Blue staining for proteoglican and Type II Collagene mRNA expression were positive after chondrocytic differentiation. Osteoblastic differentiation was obtained under the influence of dexamethasone, b-glycerol phosphate, ascorbic acid and 10% FBS. Osteogenesis was indicated by calcium accumulation (by Van Kossa staining) and by the increase in alkaline phosphatese (intracytoplasmatic staining). Osteocalcina and Bone Sialo Protein mRNA expression confirmed osteoblatic differentiation. RESULTS: bone marrow culture produced adherent cells CD45, CD14 and CD34 negative and IL-11 positive that under appropriate stimulus could differentiate into osteoblasts, chondroblasts or adipocytes. On the contrary cord blood adherent cells were CD45 and CD14 positive and CD34 and IL-11 negative and unable, to differentiate into mesenchimal cells. CONCLUSION: mesenchymal stem cells can be cultured from bone marrow but not from cord blood Percoll isolated cells. These results might be relevant in the context of stem cell transplantation Recovery of the hematopoietic system after stem cell transplantation is accompanied by proliferation of progenitor cells and such enforced divisions may cause shortening of telomeres linked to replicative senescence. Shortening of telomeres can be reduced by the enzyme telomerase. While normal peripheral blood cells express low levels of telomerase activity, telomerase activity increases significantly in malignant cells and hematopoietic CD34+ cells during ex vivo expansion with a combination of growth factors. Expression of reverse transcriptase (hTERT), telomerase RNA template (hTR) and telomerase-associated protein (TP-1) genes correlates with telomerase activity. In order to investigate whether cytotoxic chemotherapy plus G-CSF has any effect on the expression of telomerase component genes, we examined the expression pattern of TP-1, hTR and hTERT in mobilized peripheral blood mononuclear cells (PBMCs) from patients with hematological malignancies who underwent autologous hematopoietic stem cell transplantation. The expression of telomerase components in leukapheresis products has been compared to that of the PBMCs obtained at diagnosis and in complete remission. Total RNA was extracted from leukapheresis products, diagnosis and remission marrows and from cord blood samples. Messenger RNA was reverse transcribed into cDNA and then amplified with specific primers for the TP-1, hTR and hTERT genes by polymerase chain reaction. The presence of amplifiable RNA was confirmed in all samples using RT-PCR of porphobilinogen deaminase gene RNA. Preliminary results show that TP-1 and hTR are expressed in all samples examined. The levels of hTR mRNA were consistently 2-4 fold higher than TP-1 mRNA both in the cells from diagnosis and remission specimens as well as in the leukapheresis products. No significant difference in the TP-1 and hTR expression pattern within the samples from the same patient was observed. Telomere lenght and expression pattern of hTERT are currently under investigation. The current study may have implications for the reconstitution capacity of repopulating CD34+ cells after peripheral stem cell transplantation.
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Purification and osteogenic differentiation of human mesenchimal stem cells R. Saccardi, S. Urbani, R. Caporale, L. Lombardini, A. Bosi, P. Rossi Ferrini (Firenze, I) Mesenchymal stem cells (MSCs) are multipotent progenitors retaining the capability to differentiate along multiple mesenchymal subtypes (fibroblasts, chondroblasts, osteoblasts, adipocytes, smooth muscle cells) and may play an important role in a wide range of clinical applications including restoration of damaged tissues, like bone regeneration in patients affected by skeletal defects. We optimized a method for purification and expansion of marrow MSCs collected from healthy donors, analyzing: 1.cell manipulation; 2.cell concentration in primary culture; 3. culture medium; 4.expression of non-MSC surface markers; 5.osteogenic differentiation; 6.thawing method. Either buffy coat (BC) cells or Ficoll obtained MNCs were resuspended in IMDM with 10% FCS, seeded at concentrations of 10E5, 5x10E5 and 10E6 cells/cm2 in T75 flasks and finally incubated at 37°. At confluence, adherent cell layers were detached by trypsin-EDTA, resuspended in 10% FCS IMDM and analyzed by flow cytometry for the expression of CD45/CD14 Ag, in order to evaluate non-MSCs contamination. Cells were then subcultured at a concentration of 20.000 cells/cm2 in T75 flasks. In our experience, BC was more effective in terms of both time to reach confluence and speed of disappearence of CD45+/14+ component: in fact, all BC derived primary cultures achieved confluence in two weeks, regardless of their initial cell concentration. After first seeding, expression of CD45/14 was of 1,59% and 19.74% from BC and Ficoll derived cells, respectively; after second seeding it was of 0,92% and 11.23% (pϽ0.05). Buffy-coat derived MSCs were able to support a three fold proliferation after two months of culture. We analyzed cell growth with 1) Iscove's MDM + FCS10%; 2) Mesencult Medium; 3) DMEM (low glucose) +FCS10%: primary culture cells reached confluence after 14 ± 0,4 days with Iscove's MDM, after 16 ± 0,8 days with Mesencult Medium and after 28 ± 4 with DMEM (pϽ0.05). Osteogenic differentiative potential was analyzed through the addition of 100 mg/ml ascorbic acid, 10nM dexamethasone, 10 mM beta-glicerophosphate; after 3-4 weeks, MSCs assumed the cuboidal shape of osteoblasts and intense mineralization was observed with Alizarin red S staining. In order to evaluate the thawing tecnique on MSCs viability and adhesion capability, we compared a conventional technique with the NYCBB method. The latter method resulted in a shorter time to reach confluence and a higher rate of cell recovery after two weeks of culture.
P792 MAPK Activation by mu opioid-receptor in cord blood CD34+/38-cells.
G. Rozenfeld-Granot, A. Toren, N. Amariglio, A. Nagler, E. Rosenthal, M. Biniaminov, F. Brok-Simoni, G. Rechavi (Tel-Hashomer, Jerusalem, IL)
We compared 2 sources of stem cells used for allogeneic transplantation: cord blood (CB) CD34+ cells and peripheral blood (PB)G-CSF mobilized CD34+ cells. It has long been known that the CB stem cells are more primitive, they produce long term repopulating stem cells in-vivo, they grow larger colonies and have longer telomers. These properties give them a proliferative advantage that should compensate for the relatively low number of stem cells contained in a single unit of cord blood. The aims of our study were to compare the mRNA expression patterns of CB and PB CD34+ cells. This of-course can be accomplished by using standard techniques such as RT-PCR or Northern blot analysis. These methods focus only on a few candidate genes at a time and they rely on genes whose sequence is known. Alternatively we used a more relevant approach that analyzes multiple genes simultaneously. This was achieved by hybridizing an entire cDNA population to nucleic acid arrays. A single hybridization experiment generates an expression profile for hundreds or thousands of genes at once. The most prominent difference in gene expression, in favor of CB CD34+ cells, was observed in the mu-receptor gene. This receptor was mainly expressed on the CB CD34+/CD38-subpopulation. In addition to the preferential expressionof the mu-receptor in CB cells we showed the activation of a signal transduction cascade by this receptor. This was achieved by demonstrating the phosphorylation/activation of MAP kinase and by a functional assay showing phosphorylation of a known MAP kinase substrate (Elk-1) by MAP kinase. As the mu-receptor signal transduction cascade has a proliferative potential and as MAP kinase has been shown to have anti-apoptotic effects, the existence of this receptor on early CB progenitors may have a baring on CD34+ cell expansion. The existence of a traditionally regarded neuronal receptor on CB CD34+ cells will be discussed with regard to its future role in the treatment of neurological diseases.
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Do we have to protect stem cell grafts from X-ray hand luggage control systems at international airports?
H.G. Speth, E. Gunsilius, K. Eisendle, E. Hoflehner, D. Nachbaur, G. Gastl, A.L. Petzer (Innsbruck, AT)
Matched unrelated donor transplantation has become an increasing transplantation procedure for patients with hematologic malignancies and marrow or PBSC harvests are commonly transported from the harvesting center to the transplantation center by aircrafts. So far the SC grafts have to be protected from X-ray-hand-luggage-control-systems according to standard IBMTR/EBMT-guidelines. To address the question whether SC harvests have indeed to be prevented from this security procedure, we performed a series of experiments, where we exposed aliquots from BM or mobilized peripheral blood 0, 1, 2, 3, 5 and 10 times to a widely used X-ray-handluggage-control-system (HEIMANN HI-SCAN 6040 A, Wiesbaden, Germany, radiation dosage 1.5 ± 0.6 µSv/run) at Innsbruck International Airport. Cell viability as well as growth of mature (CFC) and primitive progenitor cells (LTC-IC) were analyzed thereafter and compared to control cells not exposed to irradiation. The mean cell viability was 96%+/-1 in control cells (n=8) and did not decrease after 1, 2, 3, 5 or 10 passages (P), respectively, through the Xray scan (98%+/-1, 98%+/-1, 97%+/-2, 96%+/-2, 98%+/-1). The growth of mature progenitor cells (Colony Forming Cells, CFC) was 101%+/-7 (1P), 104%+/-8 (2P) 95%+/-11 (3P) 111%+/-15 (5P) and 113%+/-13 (10P) compared to control cells (set 100% at 0 P). Primitive longterm culture initiating cells (LTC-IC) also did not decline if passed through the X-ray scan up to 10 times (106%+/-17, 91%+/-18, 126%+/-44, 141%+/-36 and 111%+/-30 after 1, 2, 3, 5 and 10 P compared to control values). These data indicate that passages up to 10 times through hand-luggage-control-systems do not seem to harm SC grafts. It has also to be considered that the cells are exposed to a radiation dosage of~60 µSv through cosmic radiation during a 10 hour flight, comparable to~40 hand luggage controls at the airport. Further investigations with this aspect should be performed to eliminate potential conflicts with security standards at international airports. Allogeneic transplantation of peripheral blood progenitor cells (PBPC) is being performed more frequently due to the shortening of aplasia after transplantation. In the great majority of cases a CD34+ cell number can be obtained. However there are a few normal donors that who do not mobilise enough CD34+ cells into PB and further apheresis are required. The present study was aimed to analyse the hematopoiesis of normal donors before G-CSF administration and ascertain whether, "in vitro", the behaviour could relate to CD34 mobilisation. Forty-three healthy donors were studied after informed consent had been obtained. Bone marrow mononuclear cells were used for clonogenic and long-term culture assays (LTC). Median age of donors was 41 years old (17-92) and male/female ratio 14/29. One apheresis was performed in 31 cases, two in 9 and 3 in only two donors. The mean of CD34+ cells obtained in the first apheresis was 31.2+/-15.8 x10 8cells. The total number of CD34+ cells was 35.5+/-15 x10 8. There were no differences in CD34 mobilisation according to sex or body weight of donor. The only parameter to influence mobilisation was age. Although only 3 cases were available, donors under 20 years showed significantly more CD34+ in the first apheresis than older patients. In order to ascertain whether the bone marrow hematopoiesis could influence CD34+ cell mobilisation, both clonogenic and LTC were analysed. The results of bone marrow cultures were as follows: granulo-monocytic progenitors (CFU-GM), 205+/-225 /10 5 cells plated; eritroid progenitors, 102+/-109 /10 5 cells plated; CFU-Mix, 8+/-16 /10 5 cells plated. Long term cultures were evaluated by the CFU-GM total production during 8 weeks of culture. The mean of CFU-GM obtained in LTC was 1196+/-803 /10 7 cells plated. The number of committed progenitor cells (CFU-GM, BFU-E and CFU-Mix) did not correlate with the number of CD34+ cells mobilised. Only CFU-GM production throughout the LTC period correlated with CD34+ cell mobilisation (r=0,66 p=0.000). LTBMC allows the study of complete hematopoiesis ( progenitor cells and stromal function) and both of them seem to influence the quantity of CD34+ cells obtained. The aim of the study was to obtain defined culture conditions for the ex-vivo expansion of PBSCs in order to increase their therapeutic potential. We investigated the role of three experimental parameters: the medium (serum-free substitute Stem Pro34, Gibco vs. serum-dependent IMDM, Life Technologies), the cell population (Ficoll-separated mononucleated cells-MNCs vs. CD34+), the recombinant cytokines Flt-3-L and/or TPO in association with a basic cocktail (BC) of SCF+IL-3+IL-6+GM-CSF+EPO. So far, seventeen leukapheresis samples were cultured for 15 days. The expansion potential was assessed every five days by total nuclear cells (TNCs) number, progenitors assay (CFU-GM, BFU-E, CFU-GEMM) and flow cytometry immunophenotyping (CD34+CD38-progenitor cells, CD38+, CD33+, CD41+, GlyA+). The results were evaluated by multivariate ANOVA with repeated measures and grouping factors; P-values (two-sided) were adjusted according to Greenhouse and Geisser. TNCs could be expanded up to 50-fold with statistical significance only for the use of CD34+ selected cells (PϽ0.000). The variable cell population (CD34+ cells) resulted statistically significative also for the expansion of late precursor cell compartment, such as CD33+ (up to 450-fold, P=0.07) and GlyA (P=0.004), and of the progenitor cell compartment, such as CFU-GM ( up to 40-fold, PϽ0.000), CFU-GEMM (up to 15-fold, P=0.007). The same impact on progenitor cell compartment expansion was evident for serum-free medium: in this case also BFU-E expansion was affected (up to 35-fold, P=0.011). Flt-3-L strongly stimulated CFU-GM expansion (P=0.011), whereas none of the other parameters studied were conditioned by cytokines combination. Flow cytometric analysis showed that CD34+/38-expressing cells were mantained to a limited degree only (up to 6-fold amplification over input cells); otherwise, cell populations committed to myeloid (CD33 and CD38), megacaryocytic (CD41, up to 280-fold) lineages predominated. Our study indicates that progenitor and late precursor multilineage cell compartments may be significantly improved in short term cultures by some conditions, such as serum-free medium, CD34+ selected cells and particular cytokines combination.
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